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patients with intermittent claudication,1 management,
besides cardiovascular risk reduction, aims essentially at
symptomatic relief and improved quality of life. Treatment
efficacy has traditionally been assessed using walking
distances. Patient-related factors associated with failure to
improve quality of life, however, have largely been ignored.
In this issue of the European Journal of Vascular and
Endovascular Surgery, Safley et al.2 propose a set of such
criteria to identify a vulnerable subset of patients with
intermittent claudication in which treatment failure is
likely.
The issue is important for several reasons. The burden of
symptomatic peripheral arterial disease on quality of life is
substantial and is in the same range as for other forms of
arterial disease.3 In contrast to the coronary or the cere-
brovascular territories, however, prognostic significance of
peripheral arterial disease and its management are likely
underestimated within primary care. Already a decade ago,
the US PARTNERS programme reported a striking degree of
negligence among primary care providers vis-a`-vis suspicion
and appropriate treatment of peripheral arterial disease.4DOI of original article: 10.1016/j.ejvs.2011.02.012.
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doi:10.1016/j.ejvs.2011.05.012Safley’s report suggests that it is still being trivialised,
even if the diagnosis has already been established. Clearly,
awareness campaigns have not penetrated primary care
sufficiently and more convincing needs to be done.
It is comforting to see that specialist referral improved
evidence-based risk-factor management effectively;
however, it may seem disappointing that dedicated care did
not improve quality of life to a similar degree but failed in
every third patient. That elderly patients with longstanding
or extensive disease initially presented with worse quality
of life is in accordance with previous reports.3 Low baseline
scores increase the odds for improvement and, indeed,
many of these patients improved considerably during
a treatment course of 2 years. Less straightforward,
however, is the interpretation of why a subset of elderly
patients, including those who suffered from bilateral
disease, had had a prior stroke or were under beta-blocker
use, seemed less likely to improve, and how the ʻeffect’ of
these non-modifiable risk factors could be
counterbalanced.
The authors have highlighted some potential study
limitations, and these need to be reiterated. The first
relates to selection bias: despite a long recruitment period
of 2 years, only 15 patients were eventually analysed on
average per participating centre. In the context of such
a low yield, consecutive recruitment is essential to prevent
selection. Adherence to this premise, although intended,d by Elsevier Ltd. All rights reserved.
364 F. Dickwas not audited and is uncertain.5 Moreover, involved
patients were mainly male Caucasians and those who did
not survive were excluded from analysis. The second
potential limitation involves the risk of confounding:
management strategies were neither standardised nor
monitored across centres. Although this may reflect the
diversity in real life, variable compliance with various
therapies may explain at least part of the differences
between the groups. For instance, the authors simply
assumed that patients were prescribed supervised exercise
training but were not able to track participation on an
individual level. Moreover, health-related quality of life is
difficult to assess in claudicants,6 and, thus, perceived
health status may be influenced by a series of additional
and unaccounted factors. The third limitation refers to the
study design: caseecontrol studies are not suited to
investigate causal relationships; therefore, presented
associations are correlations at best.
In the light of these limitations, many of the authors’
conclusions are still biologically plausible and hide an
important lesson. Even though no functional outcome data
are provided, it is probably safe to assume that health-
related quality of life correlated positively with walking
capacity.3,7 Exercise training effectively (and cost-
effectively) generates improved walking capacity8 and
remains the recommended conservative mainstay of
intermittent-claudication management.1 Nonetheless,
exercise therapy tends to be underused,9 and of all things,
participation was not tracked in the current study.2
Consideration of the characteristics of the above ‘cohort
at risk’ suggests that, as a common denominator, these
patients were less likely to undergo or adhere to exercise
training. This is an obvious source of confounding. At the
same time, it offers a promising alternative to deal with the
‘non-modifiable’ predictors of outcome.
Therefore, if the glass is to be considered half full, then
specialist referral and relatively simple and cost-effective
measures are able to satisfy essential therapeutic needs in
a large proportion of claudicants, and invasive revascular-
isation is rarely required. If, in turn, it is to be considered
half empty, a failure rate of 36% suggests ample room for
improvement, the first of which should be ensuring patient
compliance. Either way, impact of conservative measures,
such as (supervised) exercise training and best medicaltherapy, must not be underestimated, neither within study
designs nor in clinical practice and, in particular, not by
admonishers of the undervalued significance of peripheral
arterial disease, as we all should be. Only because adher-
ence to exercise training may be difficult to track under
study conditions does not mean it is impossible to apply in
real life, and this could be an important way to involve
primary care providers.References
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